Unlocking the true clinical potential of
cannabinoid-based medicines
Plant based
therapeutics
We develop APIs from IP-protected genetics, to amplify and harness the therapeutic power of the cannabis plant.
Pharmaceutical
rigor
We are experts in pharmaceutical development on the endocannabinoid system, conducting tailored pre- and clinical trials.
Regulatory
excellence
We enable a secure and fast-track to market through in-depth expertise on and adherence to the requirements of European and national regulatory authorities (EMA/BfArM) while ensuring EU GxP compliant supply chains.
Value through
collaboration
We are part of an excellent biopharma ecosystem of industry leaders, leading scientists and institutional players to create synergies and work efficiently.
We are Cannaflos, a European biopharmaceutical company
specialized in the endocannabinoid system, conducting clinical stage drug development from plant to patient.
Since 2019, we serve the medical cannabis industry with registered cannabis genetics and expertise in cultivation, production, clinical research, compliance and regulatory affairs.
Clinical-stage drug developement
We envision a future where Cannabinoid-based-medicine (CBM) is fully recognized, validated, and integrated into modern healthcare.
Therefore, we are on a mission to address critical unmet medical needs in neurology, through clinical stage development of cannabinoid-based medicines from plant to patient.
Genetics as the foundational IP for drug development
We have developed 19 highly therapeutic, EU-CPVO registered cannabis cultivars that serve as the starting material for API development to enter clinical trails. This approach lays the foundation for IP protection, batch-to-batch consistency and optimized therapeutic potential.
We are research-driven
At Cannaflos, we believe good science means good business. Therefore, we pursue an evidence based approach across all our business endeavours.
To do so, our in-house scientists work hand in hand with top-tier academic and clinical researchers around the world to advance our knowledge for the benefit of the plant, the patient and the planet.
Shaping the future of medical Cannabis, together
Cannaflos works closely with international partners in cultivation, manufacturing, research and development, and regulatory affairs. We see a special potential in European cooperation.
We serve your needs across the Cannabis value chain
Our end-to-end capabilities
Preservation
Preserving natures diversity through our germplasm bank and enabling mother renewal from in vitro.
Licensing
Cultivate one of our 19 fully traceable premium Cannabis genetics. They have been carefully developed for their unique cannabinoid composition, cultivation procedures and morphology.
consulting
Offering industry specific expertise across strategy, product, quality management, operations, regulatory and clinical trial design.
Roadmap
We support you on your way to your GACP and EU GMP licenses. Our Qualified Person has in-depth cannabis knowledge and many years of industry experience, so we can cover a wide range of compliance and product quality advice.
Network
Cannaflos has a EU pharmaceutical manufacturing license and a license for wholesale distribution of medicinal products. In addition, we have a broad and reliable network of qualified partners for packaging activities, germ reduction measures, quality analyses and stability tests.
As a pharmaceutical company, we offer you pharmaceutical services to support your entry into the German market.
Leveraging business as a force for good
Pharmaceutical manufacturers and wholesalers according to §§ 13, 52a AMG and EU GDP/GMP with a medical cannabis license according to § 4 MedCanG
Our innovative approach is promoted by